Skip to main content

Abstract

Bioactive compounds released during milk fermentation by proteolytic cleavage of milk proteins have a role beyond their nutritional importance. This study assessed the proteolytic activity of Lactobacillus helveticus strains ASCC953, ASCC474, ASCC1188, and ASCC1315 and their ability to release bioactive compounds capable of exerting antioxidative and in vitro anticarcinogenic properties during incubation at 37°C in reconstituted skim milk. The performance of these strains was not affected by the pH decline during fermentation. Soluble extracts of fermented milk by L. helveticus 474 showed the highest free radical (1,1-diphenyl-2-picrylhydrazyl) scavenging activity at 12 h of fermentation, followed by a significant reduction of this activity at 24 h compared with the other strains and control (untreated milk). Skim milk fermented by L. helveticus strains contained compounds with anti-colon cancer activity at varied levels during fermentation. The activity (19.03-50.98% growth inhibition) was greatest in the extract obtained after 12 h of fermentation, which markedly declined (5.4-9.94%) at the end of fermentation. Lactobacillus helveticus 1315 released compounds into the skim milk supernatant with a greater growth inhibition (50.98%) on colon cancer HT-29 cell line than the other strains. More importantly, these compounds had no significant inhibition effect on normal, primary colon cells T4056. Whereas these results suggest that milk fermented by L. helveticus strains may release bioactive compounds with important multifunctional properties, the characteristics and activities of these compounds appear highly strain- and fermentation time-dependent.

Keywords: Lactobacillus helveticus; anti-colon cancer; antioxidant; fermentation.

Research Insights

SupplementHealth OutcomeEffect TypeEffect Size
Lactobacillus helveticusIncreased Antioxidant ActivityBeneficial
Moderate
Lactobacillus helveticusReduced Incidence of Colon CancerBeneficial
Large
Lactobacillus helveticusSelective Anti-Colon Cancer ActivityBeneficial
Moderate
Lactobacillus helveticus L10Enhanced Antioxidant ActivityBeneficial
Large
Lactobacillus helveticus L10Reduced Incidence of Colon CancerBeneficial
Large
Lactobacillus helveticus R0052Increased Antioxidant ActivityBeneficial
Moderate
Lactobacillus helveticus R0052Reduced Incidence of Colon CancerBeneficial
Large
Lactobacillus helveticus R0052Selective Anti-Colon Cancer ActivityBeneficial
Moderate
Lactobacillus helveticus Rosell-52Increased Antioxidant ActivityBeneficial
Moderate
Lactobacillus helveticus Rosell-52Non-Toxicity to Normal Colon CellsNeutral
Moderate
Lactobacillus helveticus Rosell-52Reduced Incidence of Colon CancerBeneficial
Large
Lactobacillus helveticus Rosell-52NDIncreased Antioxidant ActivityBeneficial
Moderate
Lactobacillus helveticus Rosell-52NDNo Significant Inhibition on Normal CellsNeutral
Large
Lactobacillus helveticus Rosell-52NDReduced Incidence of Colon CancerBeneficial
Large

Pillser helps you make informed health decisions by providing comprehensive, unbiased information about supplements. This includes detailed research on supplement ingredients, their benefits, potential risks, and their overall efficacy. You can contribute by sharing your feedback and suggestions.

Send us an email at support@pillser.com.